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, the scientific community was doubtful about the significance of these findings. "It was a bit like having two Popes -it was the dendritic cells versus the macrophages", as Siamon Gordon, University of Oxford, UK, recalls in Nature (Nature News, 3 Oct 2011). Since then, the work of Ralph Steinman and numerous other investigators has unravelled the function of dendritic cells as professional antigen presenters that shape adaptive immune responses, leading to immune reactivity or tolerance (for an overview of the function of dendritic cells, see our recent Poster).
Nothing is more convincing for demonstrating the value of a scientific discovery than the successful application of the new findings to the treatment of disease. The significance of the work of Ralph Steinman is highlighted by the fact that several dendritic cell-based cancer vaccines are currently being tested in clinical trials, and last year the US Food and Drug Administration approved a treatment for prostate cancer known as sipuleucel-T (Provenge; Dendreon) 2 , which is based on patientderived dendritic cells. Remarkably, Steinman, who was diagnosed with pancreatic cancer 4 years ago, was himself treated with an experimental dendritic cell-based therapy.
The discoveries of the other two Nobel laureates have equally big potential for the development of immunebased therapies. Jules Hoffman (French National Centre for Scientific Research, Institute of Cell and Molecular Biology, Strasbourg, France) and Bruce Beutler (Scripps Research Institute, La Jolla, California, USA) share the other half of this year's Nobel Prize for their discoveries concerning the activation of innate immunity.
In 1996, Jules Hoffmann and his colleagues, primed by the parallels between immune signalling pathways in mammals and the embryonic development-associated Toll signalling pathway in Drosophila melanogaster, discovered the essential role of the cell surface receptor Toll in innate immune responses against bacteria and fungi in fruit flies 3 . The description of a role for Toll in pathogen recognition triggered an explosion in the field of innate immunity, which at that time was puzzled by how pathogen-derived signals activate innate immune cells and thus lead to the effective priming of adaptive immune responses.
One year after the publication of Hoffmann's Cell paper, the first human Toll-like receptor (TLR) genenow known as TLR4-was cloned by Metzhitov and Janeway 4 . Their work, published in Nature, showed that overexpression of a constitutively active human TLR resulted in the expression of cytokines and costimulatory molecules. Some months later, in September 1998, Godowski and colleagues reported in Nature that lipopoly saccharide (LPS)-induced gene expression depends on TLR2 signalling 5 . These key events prepared the ground for the finding by Beutler and colleagues published in December 1998 that LPS is the ligand for TLR4, as mutations in the Tlr4 gene in mice were found to result in resistance to LPSinduced sepsis 6 . It is remarkable that, since the elucidation of the role of TLRs in pathogen sensing, over 15,000 publications have focused on their immune function. In the past years, the main players in TLR signalling have been identified and numerous TLR-binding pathogenassociated and damage-associated molecular patterns have been characterized. Furthermore, synthetic TLR agonists are being tested in clinical trials for their therapeutic potential in inflammatory diseases.
In this new era of immunology, this year's Nobel Prize highlights the importance of the initial discoveries that brought the roles of dendritic cells and TLRs into focus.
